Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

NCT02771197 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Fludarabine
DRUG: Melphalan
DRUG: Pembrolizumab

Sponsor

Northside Hospital, Inc.

Collaborators

[object Object]